Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC

NCT06876844 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Head and Neck Cancer Squamous Cell Carcinoma

Interventions

DRUG: combination of Surufatinib and Envolizumab

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University